PMDA drug package insert
ベバシズマブBS点滴静注100mg「CTNK」
PMDA Prescription drug · 日本化薬株式会社 · package insert Mar 31, 2026
Key facts
| Brand names | ベバシズマブBS点滴静注100mg「CTNK」, ベバシズマブBS点滴静注400mg「CTNK」 |
|---|---|
| Nonproprietary names | ベバシズマブ（遺伝子組換え） |
| Companies | 製造販売元／日本化薬株式会社, 提携先／セルトリオン・ヘルスケア・ジャパン株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗悪性腫瘍剤／抗VEGF注1）ヒト化モノクローナル抗体 注1）VEGF：Vascular Endothelial Growth Factor（血管内皮増殖因子） |
| Therapeutic category codes | 874291 |
| YJ codes | 4291463A1020, 4291463A2027 |
| Approval numbers | 30400AMX00418, 30400AMX00419 |
| Package insert edition | 第6版 |
| Package insert date | Mar 31, 2026 |
| PMDA document key | 530191_4291463A1020_1 |
| PMDA company code | 530191 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: